MacroGenics, Inc.
MacroGenics, Inc. (MGNX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · MGNX · as of Jun 8, 2026
Key Statistics
Explore MacroGenics, Inc. Data
mgnx stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 22 · Buy rate: 54.5%
The MGNX analyst consensus is Buy, based on ratings from 22 Wall Street analysts over the past 3 months. The average 12-month price target is $6.00, representing +54.64% upside from the current price of $3.88.
Competitors & Peers
mgnx competitorsMGNX
CLNN
CNTB
CNTX
COYA
IFRXStock Performance
Full HistoryAbout MacroGenics, Inc.
MacroGenics, Inc. is a U.S.-based biopharmaceutical company specializing in the development and commercialization of antibody-derived treatments primarily aimed at combating cancer. The company's sole…
what is macrogenics, inc. · mgnx stock overview · macrogenics, inc. company profile · who is macrogenics, inc. ceo · mgnx NASDAQ · macrogenics, inc. headquarters · macrogenics, inc. business segments
About Stock Overview & Key Data
MacroGenics, Inc. (MGNX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 10, 2013. As of the latest trading session, MGNX stock price is $3.88, with a market capitalization of $246.6M. The stock has returned +136.59% over the past 12 months and +140.99% year-to-date.
According to 22 Wall Street analysts, the consensus rating for MacroGenics, Inc. stock is Buy, with an average 12-month price target of $6.00. In fiscal year 2025, MacroGenics, Inc. reported revenue of $149.5M and net income of -$74.6M. For detailed data — including MacroGenics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, MacroGenics, Inc. (MGNX) stock price is $3.88. The stock is traded on NASDAQ under the ticker symbol MGNX. The 52-week range is $1.19 – $4.64.